Bill Gates Funds a Crucial COVID-19 Vaccine Human Trial, Merck Adds 2 Candidates
Over the Memorial Day weekend, an experimental vaccine made by Maryland-based biotech firm Novavax started phase 1 clinical trial in Australia. The trial plans to enroll approximately 130 volunteers, with results coming out as soon as July. If phase 1 is successful, Novavax will move on to a phase 2 trial in more countries, including the U.S. The vaccine, called NVX‑CoV2373, proved to produce high levels of neutralizing antibodies against COVID-19 in pre-clinical testing. “These results provide strong evidence that the vaccine candidate will be highly immunogenic in humans, leading to protection from COVID‑19 and thus helping to control the spread of this disease,” the company said in a statement on Monday.
Observer - May 26, 2020View the full story here: https://observer.com/2020/05/coronavirus-vaccine-update-novavax-merck-bill-gates-funding/